tachypnea (number of breaths),
Conditions
Interventions
The control group received placebo (similar to the zinc sulfate syrup in terms of color and taste,
made by Farabi pharmaceutical company). ,received zinc sulfate (made by Farabi pharmaceutical company) as 10 mg/day in children younger than one,
and 20 mg/day in children above one year old every 12 hours (during hospitalization and most 10 days)
Active Comparator No treatment,Active Comparator Drug
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
2 Months to 59 Months
Inclusion criteria
Inclusion criteria: children 2-59-months old with a diagnosis of pneumonia based on history and clinical examination, and if necessary, chest x-ray by a pediatrician
Exclusion criteria
Exclusion criteria: Children with chronic diseases such as immunodeficiency, cystic fibrosis, renal diseases, chronic pulmonary diseases, malnutrition and chronic diarrhea, acute severe infection, history of hospitalization over the past three months, use of immunosuppressive drugs, and history of taking zinc supplements over the past two weeks were excluded. Chronic diarrhea was defined as diarrhea for more than 14 days. Malnutrition was characterized based on clinical symptoms of kwashiorkor or Marasmus or FTT. Severe infection meant severe sepsis. Further, the patients suspect of foreign bodies and gastroesophageal reflux were also excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical Symptoms of Pneumonia During hospitalization, every 12 hours tachypnea, duration of fever, coughs, intercostal retraction, hypoxia, crackles-wheezing, and durati | — |
Secondary
| Measure | Time frame |
|---|---|
| N/A N/A N/A | — |
Countries
iran
Contacts
Public ContactFarhad Heydarian
Associate Professor of Pediatrics,Department of Pediatrics, Faculty of Medicine, Mashhad University
Outcome results
None listed